Patents Assigned to Kitasato Institute
-
Publication number: 20210299240Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].Type: ApplicationFiled: October 19, 2017Publication date: September 30, 2021Applicants: DENKA COMPANY LIMITED, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASESInventors: Takafumi UENO, Kengo YOSHIKAWA, Megumi MANO, Kazuhiko KATAYAMA, Motohiro MIKI, Reiko TODAKA, Yoshimasa TAKAHASHI, Taishi ONODERA
-
Publication number: 20210292382Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.Type: ApplicationFiled: September 4, 2017Publication date: September 23, 2021Applicants: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato InstituteInventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
-
Publication number: 20210268042Abstract: The present invention relates to an anti-influenza virus agent comprising Bifidobacterium bifidum as an active ingredient.Type: ApplicationFiled: July 3, 2019Publication date: September 2, 2021Applicants: THE KITASATO INSTITUTE, THE FOOD SCIENCE INSTITUTE FOUNDATION, MEIJI CO., LTD.Inventors: Takayuki NAGAI, Hiroaki KIYOHARA, Shinji JINNO, Daisuke KOZUTSUMI
-
Patent number: 11066425Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: GrantFiled: December 29, 2020Date of Patent: July 20, 2021Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTEInventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
-
Publication number: 20210147448Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: ApplicationFiled: April 26, 2019Publication date: May 20, 2021Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTEInventors: Toshio KANAI, Sachiko KOIKE, Takayuki FUKAYA, Shunichiro UESUGI, Shingo MIZUSHIMA, Hitoshi SUDA, Yuki MIZUKAMI, Yohei IKUMA, Toshiaki SUNAZUKA, Yoshihiko NOGUCHI
-
Publication number: 20210130315Abstract: The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.Type: ApplicationFiled: November 6, 2018Publication date: May 6, 2021Applicants: Bayer Animal Health GmbH, THE KITASATO INSTITUTEInventors: Dirk HEIMBACH, Satoshi OMURA, Toshiaki SUNAZUKA, Tomoyasu HIROSE, Yoshihiko NOGUCHI, Johannes KÖBBERLING, Zhijie WU, Shuibiao FU, Wei WU, Jinfeng QIU, Liu HE, Xudong WEI
-
Publication number: 20210079110Abstract: Provided is a monoclonal antibody or a fragment thereof in which heavy-chain complementarity-determining regions (CDRs) 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 5 to 7; a monoclonal antibody or a fragment thereof in which heavy-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 5 to 7, and which has binding properties to a KK-LC-1 protein; or a monoclonal antibody or a fragment thereof which competes with the monoclonal antibody or a fragment thereof in which the heavy-chain CDRs 1 to 3 respectively consist of the amino acid sequences of SEQ ID NOs: 2 to 4 and the light-chType: ApplicationFiled: November 9, 2018Publication date: March 18, 2021Applicant: School Juridical Person the Kitasato InstituteInventors: Takashi FUKUYAMA, Hitoshi YAMAZAKI, Mariko OGI, Noritada KOBAYASHI, Yoshinobu ICHIKI, Masahiko HATAKEYAMA
-
Publication number: 20200407346Abstract: The purpose of the present invention is to provide a novel compound which has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare that are causative bacteria of MAC infection and which is different in backbone structure from known drugs for treatment of MAC infection. One aspect of the present invention relates to a compound of Formula (I) [where R1 has the same meaning as described in the specification and claims] or a salt thereof, or a solvate thereof. Another aspect of the present invention relates to a method for producing the compound of Formula (I) or a salt thereof, or a solvate thereof, and a therapeutic agent for Mycobacterium avium complex infection (MAC infection), which comprises the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient.Type: ApplicationFiled: August 30, 2018Publication date: December 31, 2020Applicants: THE KITASATO INSTITUTE, OP BIO FACTORY CO., LTD.Inventors: Hiroshi TOMODA, Nobuhiro KOYAMA, Akihiko KANAMOTO, Junko HASHIMOTO, Ikuko KOZONE
-
Publication number: 20200333474Abstract: A radiation dosimetry sol or gel, and a radiation dosimeter containing the sol or the gel as a material for radiation dosimetry. A radiation dosimetry sol or gel including a compound (A) having an excitation light-induced fluorescence property that is changed by a radiolysis product of water; and a silicate salt (B). A radiation dosimetry sol or gel including a compound (A) having an excitation light-induced fluorescence property that is changed by a radiolysis product of water; a silicate salt (B); a water-soluble organic polymer (C) having an organic acid salt structure or an organic acid anion structure; and a dispersant (D) for the silicate salt (B). A radiation dosimeter including, as a material for radiation dosimetry, the above-mentioned radiation dosimetry sol or gel.Type: ApplicationFiled: October 1, 2018Publication date: October 22, 2020Applicants: RIKEN, THE KITASATO INSTITUTE, NISSAN CHEMICAL CORPORATIONInventors: Takuya MAEYAMA, Daniel Antonio SAHADE, Takaoki TAKANASHI
-
Patent number: 10786176Abstract: A fat thickness estimating device includes a storage unit that stores information indicating relationship between fat thickness and ratio of bioelectrical impedance in a first condition and bioelectrical impedance in a second condition, a measured impedance value acquiring unit configured to acquire a measured impedance value in the first condition of a target living body and a measured impedance value in the second condition of the target living body, and an estimation unit configured to calculate a fat thickness value in the target living body based on the information and a ratio of the measured impedance value in the first condition and the measured impedance value in the second condition.Type: GrantFiled: March 6, 2015Date of Patent: September 29, 2020Assignee: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventor: Satoru Nebuya
-
Publication number: 20200131161Abstract: It is known that foods containing a carbohydrate, e.g., starch, in a large amount produce acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., asparagine, with a reducing sugar. The purpose of the present invention is to provide a novel compound which is effective in inhibiting such foods from yielding acrylamide when treated at a high temperature. Specifically, the present invention provides a compound represented by General Formula (I).Type: ApplicationFiled: March 16, 2018Publication date: April 30, 2020Applicants: THE KITASATO INSTITUTE, BF AGRO CO., LTD.Inventors: Satoshi OMURA, Yoko TAKAHASHI, Takuji NAKASHIMA, Hirotaka MATSUO, Kenichi NONAKA, Hisako SAKATO
-
Patent number: 10538521Abstract: The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 25, 2017Date of Patent: January 21, 2020Assignees: CARNA BIOSCIENCES, INC., THE KITASATO INSTITUTEInventors: Masaaki Sawa, Yuko Asamitsu, Yuko Uno, Satoshi Omura, Kazuhiko Otoguro, Masato Iwatsuki, Aki Ishiyama, Rei Hokari
-
Publication number: 20190376053Abstract: The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.Type: ApplicationFiled: February 9, 2018Publication date: December 12, 2019Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE KITASATO INSTITUTEInventors: Joshua SAKON, Jeffrey ROESER, Ryan BAUER, Katarzyna JANOWSKA, Keisuke TANAKA, Osamu MATSUSHITA, Kentaro UCHIDA
-
Publication number: 20190345154Abstract: The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 25, 2017Publication date: November 14, 2019Applicants: CARNA BIOSCIENCES, INC., THE KITASATO INSTITUTEInventors: Masaaki SAWA, Yuko ASAMITSU, Yuko UNO, Satoshi OMURA, Kazuhiko OTOGURO, Masato IWATSUKI, Aki ISHIYAMA, Rei HOKARI
-
Patent number: 10412958Abstract: Provided is a device for vitrification-based cryopreservation which enables easy and reliable vitrification freezing of cells or tissues. The device of the present invention for cell or tissue cryopreservation by vitrification has a porous structure made of a material having a refractive index of 1.45 or less as a vitrification solution absorber.Type: GrantFiled: October 17, 2014Date of Patent: September 17, 2019Assignees: SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, MITSUBISHI PAPER MILLS LIMITEDInventors: Kenji Momozawa, Atsushi Matsuzawa, Katsumitsu Susaki
-
Publication number: 20190249163Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: February 22, 2019Publication date: August 15, 2019Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSA S, The Kitasato Institute, MONTEFIORE MEDICAL CENTER, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERISTYInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Patent number: 10364415Abstract: To provide an effective 1,4-dioxane-degrading bacteria culture method. Provided is a 1,4-dioxane-degrading bacteria culture method in which 1,4-dioxane-degrading bacteria are propagated using a medium containing diethylene glycol.Type: GrantFiled: October 7, 2015Date of Patent: July 30, 2019Assignees: TAISEI CORPORATION, OSAKA UNIVERSITY, SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventors: Norifumi Yamamoto, Yuji Saito, Michihiko Ike, Masashi Kuroda, Kazunari Sei, Daisuke Inoue
-
Patent number: 10357179Abstract: A length measurement device includes a tape portion (10) which is provided with a plurality of electrode pads (100a, 100b, 101a, 1010b, . . . ) arrayed thereon and is used in a state being wound around a measuring object, an impedance acquisition unit that selects any pair of electrode pads from a plurality of electrode pads and acquires electrical impedance between the pair of electrode pads, and a length calculation unit that calculates a length between the pair of electrode pads, based on a change in impedance of the pair of electrode pads.Type: GrantFiled: September 19, 2014Date of Patent: July 23, 2019Assignee: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventor: Satoru Nebuya
-
Patent number: 10330620Abstract: A detection device includes: a frequency property acquisition unit that acquires a frequency property when an alternating-current signal is input to at least two conductive bodies provided on a fiber sheet; and a detection signal output unit that outputs a detection signal when the frequency property acquisition unit acquires a predetermined frequency property.Type: GrantFiled: April 7, 2015Date of Patent: June 25, 2019Assignee: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventor: Satoru Nebuya
-
Patent number: 10307356Abstract: Provided are: a method for producing a mycrosporine-like amino acid (MAA) that includes a step in which microbes are cultivated that produce MAA on the outside of bacterial cells, a step in which the bacterial cells and extracellular culture fluid are separated, and a step in which the MAA is recovered from the extracellular culture fluid; an MAA indicated by formula (1), an MAA produced using this method, or an ultraviolet-absorbing composition including the MAA indicated by formula (1); and a composition including the MAA produced using this method or the MAA indicated by formula (1), for preventing at least one symptom or disease selected from a group comprising acute skin reactions, aging of the skin, and skin cancer.Type: GrantFiled: May 12, 2015Date of Patent: June 4, 2019Assignees: THE KITASATO INSTITUTE, NAGASE & CO., LTD.Inventors: Haruo Ikeda, Shogo Yamamoto, Jun Matsumoto, Masahiro Sota